Skip to content
1st Counsel – Lifestyle
Author:
Arletta Pharma Solutions
Arletta Pharma Solutions Appoints Jeannette Jager-van Dijk as Chief Executive Officer
September 1, 2026
Arletta Pharma Solutions Receives FDA Response Supporting the Clinical Development Program of Lybrido™ for Female Sexual Interest/Arousal Disorder in the US
July 16, 2026
Arletta Pharma Solutions Receives FDA Response Supporting the Clinical Development Program of Lybrido™ for Female Sexual Interest/Arousal Disorder in the US
July 16, 2026
Arletta Pharma Solutions Appoints Steve van Os, MD, as Chief Medical Officer
June 19, 2026